Darling Ingredients Introduces Nextida® NxCogni™, the First Targeted Collagen Peptide Designed to Support Clarity and Cognitive Resilience
Darling Ingredients, through its health brand Rousselot, introduced Nextida NxCogni, the first targeted collagen peptide ingredient formulated to support clarity and cognitive resilience in dietary supplements. The non-stimulant ingredient contains more than 10 neurosupportive peptides at concentrations exceeding 100 times those found in standard hydrolyzed collagen, with clinical trials beginning in December 2026.
Key figures
- Drug Name
- Nextida NxCogni
- Phase Of Trial
- Open-label human study (Dec. 2026) followed by two randomized controlled trials planned Q1 2027
- Facilities
- over 260
- World collagen share
- about 30%
- Neurosupportive peptides
- more than 10
- Concentration vs standard
- over 100 times standard hydrolyzed collagen
- World animal byproduct share
- about 15%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.